Rovi warns analyst profit consensus is too high, cites CDMO slowdown
Spanish drugmaker Rovi warned this month that analyst consensus estimates for its annual profits in 2024 are likely 10% to 15% too high. The CDMO said its slimmed-down profit outlook is “due basically to lower expected activity in the contract manufacturing business (CDMO) during the fourth quarter of 2024.”
Spanish drugmaker Rovi warned this month that analyst consensus estimates for its annual profits in 2024 are likely 10% to 15% too high. The CDMO said its slimmed-down profit outlook is “due basically to lower expected activity in the contract manufacturing business (CDMO) during the fourth quarter of 2024.”
